Bolt Biotherapeutics Overview
Industry: Biotechnology
Sector: Healthcare
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-2034, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California. Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in Phase II clinical trial for the treatment of patients with human epidermal growth factor receptor Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Bolt Biotherapeutics into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $0M (+2166567% YoY). Net loss was -$7,244. Cash was $23.9M.
Revenue
$0M
+2166567% YoY
Net loss
-$7,244
reported
Cash
$23.9M
reported
What changed
- Revenue +2166567% YoY to $0M.
Guidance / outlook
the Company expects to present initial clinical data in the third quarter of 2026. • Next-generation Boltbody™ ISACs targeting CEA and PD-L1. Two additional ISAC programs in Bolt’s pipeline are currently on hold.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 12, 2026
SEC filing
8-K
May 12, 2026
SEC filing
8-K
Mar 12, 2026
Earnings release
Earnings release
Mar 12, 2026
SEC filing
10-K
Mar 12, 2026
SEC filing
10-Q
Nov 12, 2025
SEC filing
8-K
Nov 12, 2025
Earnings release
Earnings release
Nov 12, 2025
Earnings release
Earnings release
Aug 14, 2025
SEC filing
10-Q
Aug 14, 2025
SEC filing
8-K
Aug 14, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Bolt and MapUp Partner for Transparent Toll Pricing Across Global Markets
Headline from PR Newswire: Bolt and MapUp Partner for Transparent Toll Pricing Across Global Markets.
Vadzo Imaging Positions the Bolt-1335CRO AR1335 OIS MIPI Camera as the Ideal Camera for UAV and Drones
Headline from Yahoo Finance: Vadzo Imaging Positions the Bolt-1335CRO AR1335 OIS MIPI Camera as the Ideal Camera for UAV and Drones.
Earnings Per Share
Score 3.00/5
Bolt Biotherapeutics boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Biotechnology industry
, Halozyme Therapeutics Inc
, Corcept Therapeutics Incorporated
, Exelixis Inc
are companies with high ratings.
Return on Equity
Score 1.27/5
Bolt Biotherapeutics exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0.59/5
Bolt Biotherapeutics
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 2.78/5
Bolt Biotherapeutics
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios